(CercleFinance.com) – Paxlovid, the new antiviral marketed by Pfizer, will be the subject of a clinical study devoted to the treatment of long Covid, we learned on Friday.
In a document filed on the ClinicalTrials.gov site, the researchers behind the trial – led by a professor from Duke University – indicate that the tests will be spread over a period of one year, namely from January 2023 to January 2024.
The 1,700 participants recruited into the study will be given three tablets of Paxlovid twice a day for 15 days.
This trial is part of the extension of the ‘Recover’ research program launched by the National Institutes of Health (NIH) to learn more about the long-term effects of the coronavirus.
Paxlovid, a combination of two antivirals, nirmatrelvir and ritonavir, is now approved for the treatment of adults with a mild or moderate form of Covid who are at high risk of progressing to serious disease, including a risk hospitalization or death.
Nirmatrelvir, its active ingredient, blocks the reproduction of the virus.
Pfizer shares were up 2.9% on Friday on the New York Stock Exchange following this information.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
Are you following this action?
Receive all the information about Pfizer in real time: